Healthcare
Live Price
Offline$0.00242
-10.37% today
Window Change
+10.00%
Window
May 29, 2026 → Jun 18, 2026
Historical coverage is still filling in
This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.
Coverage: 15 bars · May 29, 2026 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
REMSleep Holdings, Inc. (RMSL) is a Healthcare stock with a market cap of $10.00M and listed on OTC. The stock last traded around $0.00 and up 10.0% across the available one-year price window (May 29, 2026 → Jun 18, 2026). Baseline metrics include revenue growth of -85.7%, EPS growth of -275209900.0%, a dividend yield of 0.0%. What stands out right now is revenue -85.7%, EPS -275209900.0%, free cash flow -62249933.1% with operating margin -16552.7% and ROIC -0.0%. Valuation already assumes a fairly strong business story at price/sales 466.2. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines RMSL price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RMSL
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
RMSL Max Drawdown
-36.32%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for RMSL and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$1.8M
+62.3% YoY
Free Cash Flow
-$372.0K
+10.8% YoY
Revenue Growth
-85.7%
EPS Growth
-275209900.0%
Gross Margin
-4.9%
Net Margin
-18062914897.4%
Income statement
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 117K | 204K | 321K | 0 | 0 |
| Gross Profit | 18K | -757K | 72K | -58K | -49K |
| Operating Income | -794K | -2M | -1M | -426K | -470K |
| EBITDA | -861K | -2M | -1M | -368K | -515K |
| Net Income | -1M | -2M | -1M | -5M | -2M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Cash & Equivalents | 463K | 719K | 2M | 3M | 114K |
| Total Assets | 592K | 1M | 3M | 3M | 231K |
| Total Liabilities | 255K | 276K | 652K | 880K | 1M |
| Shareholder Equity | 337K | 931K | 3M | 3M | -870K |
| Total Debt | 26K | 178K | 451K | 417K | 277K |
| Net Debt | -438K | -541K | -1M | -3M | 163K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
335K
+4.2% YoY
Capital Expenditures
37K
+45.4% YoY
Free Cash Flow
372K
+10.8% YoY
Key ratios
Gross Margin
-4.9%
Operating Margin
-16552.7%
Net Margin
-18062914897.4%
ROE
-1796132454.6%
Debt / Equity
817385.07x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.